The article focuses on the study of Poeck and colleagues on short interfering RNA (siRNA). It states that siRNA acts as a potent antitumour agent not only by silencing the expression of the anti-apoptotic gene B-cell lymphoma 2 (Bcl2) but also by activating the innate immune receptor retinoic-acid-inducible gene I (RIG-I) to induce an antitumour immune response. It notes that RIG-I is known to detect RNA molecules containing 5'-triphosphate groups.